RougeTx Launches With $58M Series A for Rare Vascular Disease
RougeTx launched with $58 million to advance a potential disease-modifying treatment for hereditary hemorrhagic telangiectasia and expand its vascular-biology platform.
RougeTx has launched with a $58 million Series A to advance a potential disease-modifying treatment for hereditary hemorrhagic telangiectasia (HHT), a rare inherited bleeding disorder.
The round was co-led by BioGeneration Ventures, Angelini Ventures and Kurma Partners, with participation from Epidarex Capital, Vesalius Biocapital Partners, ROM Utrecht Region, p53 Invest and Kerna Ventures. An EIB co-investment facility also supports the financing through Angelini Ventures.
What RougeTx is targeting
RougeTx is focused on vascular instability linked to pericyte dysfunction. Its lead program is intended as a once-daily oral treatment for HHT, while the company's periSCOPE platform is designed to identify additional diseases where restoring vascular stability could be therapeutically useful.
Why the Series A is notable
The company is entering the market with a large early-stage round before clinical proof. That is typical of platform biotech only when investors believe the underlying biology can support more than one asset.
The main milestones are therefore scientific: preclinical validation, toxicology, manufacturing readiness and a credible path into first-in-human studies. If the HHT program works, the platform claim becomes more valuable; if it fails, the breadth of the periSCOPE thesis will be tested quickly.
Follow Venture Capital Tracker in Google
Add VCT as a preferred source to make our venture-capital coverage easier to find in Google Search.
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.
